본문 바로가기
KERD
논문KCI 등재

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

장승훈|이계영|김영철|이재철
대한암학회 (Korean Cancer Association)|2013.06|Cancer Research and Treatment|제45권 제2호|pp. 79-85

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

NeoplasmsDrug resistanceNon-small-cell lung carcinomaEGFR tyrosine kinase inhibitor
주제분류의학일반

초록

Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors (TKIs) as a first choice of treatment. The median response duration of TKIs as a first-line treatment for EGFR mutant tumors ranges from 11 to 14 months. However, acquired resistance to EGFR-TKIs is inevitable due to various mechanisms, such as T790M, c-Met amplification, activation of alternative pathways (IGF-1, HGF, PI3CA, AXL), transformation to mesenchymal cell or small cell features, and tumor heterogeneity. Until development of a successful treatment strategy to overcome such acquired resistance, few options are currently available. Here we provide a summary of the therapeutic options after failure of first line EGFR-TKI treatment for NSCLC.

Abstract

Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors (TKIs) as a first choice of treatment. The median response duration of TKIs as a first-line treatment for EGFR mutant tumors ranges from 11 to 14 months. However, acquired resistance to EGFR-TKIs is inevitable due to various mechanisms, such as T790M, c-Met amplification, activation of alternative pathways (IGF-1, HGF, PI3CA, AXL), transformation to mesenchymal cell or small cell features, and tumor heterogeneity. Until development of a successful treatment strategy to overcome such acquired resistance, few options are currently available. Here we provide a summary of the therapeutic options after failure of first line EGFR-TKI treatment for NSCLC.

참고문헌 (42)

  1. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
  2. Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
  3. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
  4. Zhou C, "Erlotinib versus chemotherapy as first-line treatment for pa- tients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
  5. Rosell R, "Screening for epidermal growth factor receptor mutations in lung cancer", N Engl J Med, 361, pp.958~967 (2009)
  6. Zhang Z, "Activation of the AXL kinase causes resistance to EGFRtargeted therapy in lung cancer", Nat Genet, 44, pp.852~860 (2012)
  7. Fariz Nurwidya, "Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer", Cancer Research and Treatment, 44(3), pp.151~156 (2012), 대한암학회
  8. Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 2011(3), pp.75ra26~ (2011)
  9. Nagahiro Saijo, "Present Status and Problems on Molecular Targeted Therapy of Cancer", Cancer Research and Treatment, 44(1), pp.1~10 (2012), 대한암학회
  10. Miller VA, "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b", 3 randomised trial, 2012, pp.13, 528~538
  11. National Comprehensive Cancer Network, "NCCN Clinical Practice Guidelines in Oncology, Lung Cancer Screening", ~ (2013)
  12. Wu SG, "Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations", Lung Cancer, 72, pp.333~339 (2011)
  13. Park JH, "EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer", Lung Cancer, 77, pp.433~437 (2012)
  14. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
  15. Chaft JE, "Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design", Clin Cancer Res, 17, pp.6298~6303 (2011)
  16. Riely GJ, "Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus", Clin Cancer Res, 13, pp.5150~5155 (2007)
  17. Yang JJ, "Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer", Lung Cancer, 79, pp.33~39 (2013)
  18. Jackman DM, "Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with highdose gefitinib", J Clin Oncol, 24, pp.4517~4520 (2006)
  19. Costa DB, "CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib", J Clin Oncol, 29, pp.e443~e445 (2011)
  20. Yu HA, "Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors", J Thorac Oncol, 8, pp.346~351 (2013)
  21. Hidalgo M, "Phase I and pharmacologic study of OSI- 774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies", J Clin Oncol, 19, pp.3267~3279 (2001)
  22. Baselga J, "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types", J Clin Oncol, 20, pp.4292~4302 (2002)
  23. Shepherd FA, "Erlotinib in previously treated non-small-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
  24. Thatcher N, "Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)", Lancet, 366, pp.1527~1537 (2005)
  25. Cho BC, "Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib", J Clin Oncol, 25, pp.2528~2533 (2007)
  26. Lee DH, "Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment", Ann Oncol, 19, pp.2039~2042 (2008)
  27. Viswanathan A, "Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer", Lung Cancer, 50, pp.417~418 (2005)
  28. Costa DB, "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib", Clin Cancer Res, 14, pp.7060~7067 (2008)
  29. Sim SH, "Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma", Lung Cancer, 65, pp.204~207 (2009)
  30. Wong AS, "Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer", J Thorac Oncol, 3, pp.400~404 (2008)
  31. Zhou ZT, "Erlotinib in advanced non-small-cell lung cancer after gefitinib failure Cancer", Chemother Pharmacol, 64, pp.1123~1127 (2009)
  32. Vasile E, "Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib", J Thorac Oncol, 3, pp.912~914 (2008)
  33. Becker A, "Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment", Eur J Cancer, 47, pp.2603~2606 (2011)
  34. Yokouchi H, "Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer", BMC Cancer, 7, pp.51~ (2007)
  35. Oh IJ, "Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study", Lung Cancer, 77, pp.121~127 (2012)
  36. Asahina H, "Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib", Oncology, 79, pp.423~429 (2010)
  37. Ramalingam SS, "Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer", J Clin Oncol, 30, pp.3337~3344 (2012)
  38. Yang JC, "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial", Lancet Oncol, 13, pp.539~548 (2012)
  39. Kwak E, "The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer", Oncologist, 16, pp.1498~1507 (2011)
  40. Zhou W, "Novel mutant-selective EGFR kinase inhibitors against EGFR T790M", Nature, 462, pp.1070~1074 (2009)
  41. Janjigian YY, "Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib", J Clin Oncol, 29(S), pp.7525~ (2011)
  42. Sadiq AA, "MET as a possible target for non-smallcell lung cancer", J Clin Oncol, 31, pp.1089~1096 (2013)

관련 논문AI추천

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned이대호, Mauro Orlando, Rebecca Cheng, Vichien Srimuninnimit, Xin Wang대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations김기환, 김동완, 김범석, 김세현, 김유정, 김진수, 김태민, 박세훈, 이세훈, 이종석, 허대석대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib김동완, 김미소, 김범석, 김소연, 김슬기, 김태민, 안용운, 허대석대한암학회 · Cancer Research and Treatment2019 · 제51권 제3호EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation구보미, 박근칠, 박세훈, 선종무, 안명주, 안진석, 이세훈, 정현애대한암학회 · Cancer Research and Treatment2020 · 제52권 제4호The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung AdenocarcinomaChia-Hung Hsu, Gee-Chen Chang, Huei-Wen Chen, Jeng-Sen Tseng, Jeremy J. W. Chen, Kang-Yi Su, Kun-Chieh Chen, Kuo-Hsuan Hsu, Sung-Liang Yu, Tsung-Ying Yang, Yen-Hsiang Huang대한암학회 · Cancer Research and Treatment2018 · 제50권 제4호Challenges in the Use of Targeted Therapies in Non–Small Cell Lung CancerAlex A. Adjei, Dipesh Uprety, Joel Rivera-Concepcion대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호

이 간행물의 다른 논문 (9건)

Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey, 2004-2012서민아, 최귀선, 이윤영, 전재관pp. 86-94Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis김승준, 이동수, 강진형, 김연실, 이교영, 이창걸, 최영진pp. 95-102Which Patients Might Benefit from Postmastectomy Radiotherapy in Breast Cancer Patients with T1-2 Tumor and 1-3 Axillary Lymph Nodes Metastasis?홍성언, 공문규pp. 103-111Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement김확, 류헌모, 배성화, 양덕환, 송홍석, 김형준, 김진영, 박건욱, 문준호, 김종광, 권기영, 손상균, 이경희, 김민경, 김여경, 도영록, 이제중, 현명수, 이수정, 강병욱, 채의수pp. 112-117Expression of Transforming Growth Factor β1 and E-Cadherin Proteins in Pulmonary Adenocarcinoma: Its Significance in Tumor Progression유진영, 김치홍, 박손야영주pp. 118-125
원문 보기